Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

October 6, 2025

- *Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellence*

- *Appointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI*

FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer.

"We welcome Sanjeev to Phathom's leadership team at this important stage of our growth," said Steve Basta, President and Chief Executive Officer of Phathom. "His extensive financial and operational expertise will be critical as we execute our strategy to achieve profitability and drive long-term shareholder value."

Mr. Narula commented, "This is an exciting moment to join Phathom, with VOQUEZNA gaining traction and a clear path for continued growth. I look forward to working with the talented team to drive financial performance and help unlock the company's full potential."

About Sanjeev Narula
Sanjeev Narula most recently served as Chief Financial Officer at Intra-Cellular Therapies, where he oversaw finance leading up to its $14.6 billion acquisition by Johnson & Johnson and played a key role in capital strategy, M&A, and financial planning. He previously served as CFO of Viatris and CFO of Upjohn, a former Pfizer division, where he gained extensive global experience across commercial, R&D, Information Technology, and global supply functions.

During his 16 years at Pfizer, he held senior finance roles, including CFO for Pfizer's Essential Health Business and CFO of the Primary Care Business Unit, then the company's largest commercial division. Earlier in his career, he held leadership positions at American Express and Xerox.

Mr. Narula earned his bachelor's degree in accounting and economics from the University of Delhi and is a Chartered Accountant from the Institute of Chartered Accountants of India.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of *H. pylori* infection in adults. For more information about Phathom, visit the company's website at www.phathompharma.com follow on LinkedIn and X.

Forward Looking Statement
This press release contains forward-looking statements, including without limitation statements regarding: our strategy, plans and expectations as to future profitability, growth, performance, and shareholder value. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: we may not achieve results from the commercialization of VOQUEZNA at the levels we expect; the market opportunity for VOQUEZNA may be significantly smaller than our expectations; market acceptance for VOQUEZNA from healthcare professionals, patients, and payors in the indications for which it is approved may be significantly lower than we anticipate; we may encounter coverage, reimbursement, market access, or other issues in the course of our commercialization efforts that may negatively impact our efforts and results; the size of the market opportunity and unmet need for new treatment options may not be as high as we anticipate; our results may be negatively impacted by the launch of competitive products; we may experience adverse impact as the result of our dependence on third parties in connection with supply chain and product manufacturing; we may be negatively impacted by regulatory developments or other governmental actions in the United States, including government healthcare reform; we may encounter unexpected adverse side effects or inadequate efficacy of VOQUEZNA that may limit or impair market acceptance, or may result in recalls, withdrawals or product liability claims; if we were to breach our license agreement with Takeda for vonoprazan, Takeda might take action, including termination, that would significantly impair our business; our operating expenses may be higher than we anticipate, including if we decide to engage in activities not currently in our plan or if we face unexpected, or higher than anticipated, expenses, including as the result of unexpected events such as litigation; depending on our results and activities, we may not achieve growth or profitability on the timelines we expect or at all; and any of the foregoing or other factors may negatively impact our ability to achieve our plans, goals, mission, vision and potential. For additional discussion of these and other risks, see the risk disclosure in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this presentation to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in

their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com